India-US trade relationship to grow: US Trade Representative Michael Froman Back to News & Events List


Describing the reforms undertaken by the Indian government as work in progress, a top Obama Administration official has linked the growth in bilateral trade between the two countries to India opening up and liberalising its economy. 

Prime Minister Modi came in with a very ambitious agenda, including to improve the business environment, the Make in India initiative, the Digital India initiative," US Trade Representative Michael Froman told PTI in an exclusive interview ahead of his next week's travel to India to attend the US-India Trade Policy Forum meeting. 

There have been a number of important reforms - the Goods and Services Tax bill, the Bankruptcy Law, the creation of commercial courts, the issuance of a national IP strategy, the opening of certain sectors to investment -- that are important and help contribute to a better business environment, he said. 

However, it is a work in progress, and there continues to be issues around investment and restrictions that can be addressed in order to improve the business environment," said Froman who is scheduled to travel to Mumbai and New Delhi next week. 

One of the key architect of India-US trade relationship in the Obama Administration, Froman said India had been successful in increasing its growth rate, and is now one of the fastest growing economies in the world. 

We both care a lot about strong copyright protection and the enforcement of copyrights, and the new (Indian) National Policy includes a focus on trade secrets, which we think is important. We appreciate the process that India went through in developing its IPR Policy, he said. 

We continue to work in the pharmaceutical area, and we very much believe that there is no contradiction in promoting innovation and promoting access, Froman said. 

Asserting that the US is very much committed to the public health objective, Froman said with the government of India, the Obama Administration had talked about a whole array of issues about access to medicines, including tariffs on imported medicine and opening up the health services market so that there are more providers in the market. 

We try to take a holistic approach to this, he noted. 

The US Food and Drug Administration (FDA) has a very high safety standards, he said, when asked about the delay in FDA's clearances for Indian drug and pharma companies. 

We do not compromise that for anybody. The primary mandate of the FDA is safety. I'm sure it is a process that takes some concerted effort, but at the end of the day, it means that Indian firms will be meeting a very high standard, he observed.

Original Source: economictimes.indiatimes.com


Recent News


18

04/2018
APEDA-PHDCCI to host Reverse Buyers and Sellers Meet to promote mango exports

In a bid to Promote Export of Mango and Mango products, APEDA, Ministry of Commerce and Industry in association with PHD chamber of Commerce and Industry, is organizing the Re...

09

04/2018
Over 8,500 startups recognised as on March 30

Minister of State of Commerce & Industry C. R Chaudhary on Wednesday said that a total of 8,625 Start-ups have been recognised as on 30 March, 2018.    ...

31

03/2018
India, China to resolve agri, pharma trade issues in shadow of trade war

India-China trade talks, which ended on Tuesday, saw the two countries signing joint minutes, beating the earlier record of 2014 when it took almost a month to agree on a stat...

24

03/2018
Foreign Trade Policy review last year stressed on phasing out export sops

Long before the US lashed out at India for exceeding the time period for giving subsidies to its exporters, the government had taken cognisance of the fact that the existing e...